Comparing Standard-Dose and High-Dose Cetirizine for Acute Urticaria

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorUniversity of Phayao

About this trial

The goal of this clinical trial is to learn whether a higher dose of cetirizine works better than the standard dose to relieve symptoms of acute urticaria (hives) in adults. The study also aims to learn about the safety of taking a higher dose for a short period of time. The main questions the study aims to answer are:

1. Does the higher dose of cetirizine help people with acute urticaria improve faster than the standard dose? 2. What side effects do participants experience when taking the higher dose?

Researchers will compare two groups:

one group taking the standard dose of cetirizine (10 mg per day) and another group taking a higher dose (40 mg per day). This will help researchers understand which dose works better and whether the higher dose is safe.

Participants will:

Take the assigned study medication for 7 days Record their daily symptoms, including itch and hive severity Return for follow-up visits on Day 3, Day 7, and Week 6 Have blood tests to check liver and kidney function before and after treatment

This study may help improve treatment options for people with acute urticaria and reduce the need for unnecessary steroid use.

Eligibility criteria

Qualifiers

Adults aged 18 to 60 years

Clinical diagnosis of acute urticaria made by a physician

Onset of new wheals within the past 24 hours

Able and willing to comply with study procedures, complete symptom diaries, and attend follow-up visits

Disqualifiers

Use of systemic corticosteroids within the past 5 days

Use of immunosuppressive medications within the past 5 days

Clinical signs of anaphylaxis, including respiratory distress, hypotension, abdominal pain, or acute laryngeal swelling

Presence of angioedema without wheals

Trial design

Treatments tested in this trial

  • Cetirizine 10 mg once daily
  • Cetirizine 20 mg twice daily, total 40 mg/day

Treatment groups

140 Participants
are divided into 2 treatment groups

Sponsors and collaborators